Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Pilots Faster Pre-Qualification Procedure For IVDs

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics are assessed by the World Health Organization to support use for priority diseases in low-resource regions. Under a new WHO process, performance evaluations for IVDs may be initiated at a much earlier stage than is currently allowed.

You may also be interested in...



WHO Plans New Fees For IVD Prequalification In Early 2018

A new fee structure for the prequalification of in vitro diagnostics by the World Health Organization is expected to come into effect in early 2018 following the introduction of a fee-for-service framework for medicines and vaccines in January 2017.

New WHO Prequalification Fees To Reap $20m A Year; Prices Could Rise As A Result

A new financing arrangement due to take effect in January 2017 will see manufacturers paying fees for the World Health Organization’s prequalification program in an effort to give it a firmer footing in the long term. While manufacturers have welcomed the new fee structure, the NGO Health Action International says safeguards will be needed to ensure regulation remains robust.

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel